HSPA7 was found to be a risk factor in the cohort of melanoma patients who received anti-CTLA4 therapy (Figures 6A–C) but was found to be a beneficial prognostic factor in the TCGA SKCM cohort (23) (Supplementary Figures S14, S16), exhibiting no obvious correlation with immune checkpoint expression (Supplementary Figure S20A) or the immune response (Supplementary Figure S20B). This evidence concerns the gene CTLA4 and melanoma.